BIO 2025

R&D

Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.

News

FDA Commissioner Marty Makary has revealed a new priority review voucher programme for new medicines deemed to be of national priority for the US.

Market Access

FDA Commissioner Dr Martin Makary took the stage at BIO 2025 to detail the way he and his team have been challenging “deeply held assumptions”.

R&D

Massachusetts Governor Maura Healey took shots at the Trump Administration as she announced $40M in life sciences tax incentives at BIO 2025.

News

Genentech's Fritz Bittenbender becomes chair of the Biotechnology Innovation Organization at a challenging time for the sector.

Digital

At BIO 2025 in Boston today, pharma and biotech leaders discussed the current state of AI in the drug development life cycle.